385 related articles for article (PubMed ID: 34015288)
1. Toxicity and biodistribution assessment of curcumin-coated iron oxide nanoparticles: Multidose administration.
Aboushoushah S; Alshammari W; Darwesh R; Elbaily N
Life Sci; 2021 Jul; 277():119625. PubMed ID: 34015288
[TBL] [Abstract][Full Text] [Related]
2. Long-term biodistribution and toxicity of curcumin capped iron oxide nanoparticles after single-dose administration in mice.
Elbialy NS; Aboushoushah SF; Alshammari WW
Life Sci; 2019 Aug; 230():76-83. PubMed ID: 31128136
[TBL] [Abstract][Full Text] [Related]
3. Surface modifications affect iron oxide nanoparticles' biodistribution after multiple-dose administration in rats.
Fahmy HM; Abd El-Daim TM; Ali OA; Hassan AA; Mohammed FF; Fathy MM
J Biochem Mol Toxicol; 2021 Mar; 35(3):e22671. PubMed ID: 33295111
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution, pharmacokinetics, and toxicity of dendrimer-coated iron oxide nanoparticles in BALB/c mice.
Salimi M; Sarkar S; Fathi S; Alizadeh AM; Saber R; Moradi F; Delavari H
Int J Nanomedicine; 2018; 13():1483-1493. PubMed ID: 29559777
[TBL] [Abstract][Full Text] [Related]
5. Biodistribution, Clearance And Morphological Alterations Of Intravenously Administered Iron Oxide Nanoparticles In Male Wistar Rats.
Gaharwar US; Meena R; Rajamani P
Int J Nanomedicine; 2019; 14():9677-9692. PubMed ID: 31827324
[TBL] [Abstract][Full Text] [Related]
6. FTIR microspectroscopy revealed biochemical changes in liver and kidneys as a result of exposure to low dose of iron oxide nanoparticles.
Drozdz A; Matusiak K; Setkowicz Z; Ciarach M; Janeczko K; Sandt C; Borondics F; Horak D; Babic M; Chwiej J
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Aug; 236():118355. PubMed ID: 32344375
[TBL] [Abstract][Full Text] [Related]
7. Antidepressant effects of curcumin-coated iron oxide nanoparticles in a rat model of depression.
Khadrawy YA; Hosny EN; Magdy M; Mohammed HS
Eur J Pharmacol; 2021 Oct; 908():174384. PubMed ID: 34324858
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution of negatively charged iron oxide nanoparticles (IONPs) in mice and enhanced brain delivery using lysophosphatidic acid (LPA).
Sun Z; Worden M; Thliveris JA; Hombach-Klonisch S; Klonisch T; van Lierop J; Hegmann T; Miller DW
Nanomedicine; 2016 Oct; 12(7):1775-1784. PubMed ID: 27125435
[TBL] [Abstract][Full Text] [Related]
9. Hepatotoxic and Neurotoxic Potential of Iron Oxide Nanoparticles in Wistar Rats: a Biochemical and Ultrastructural Study.
Mabrouk M; Ibrahim Fouad G; El-Sayed SAM; Rizk MZ; Beherei HH
Biol Trace Elem Res; 2022 Aug; 200(8):3638-3665. PubMed ID: 34704196
[TBL] [Abstract][Full Text] [Related]
10. New Insight about Biocompatibility and Biodegradability of Iron Oxide Magnetic Nanoparticles: Stereological and In Vivo MRI Monitor.
Nosrati H; Salehiabar M; Fridoni M; Abdollahifar MA; Kheiri Manjili H; Davaran S; Danafar H
Sci Rep; 2019 May; 9(1):7173. PubMed ID: 31073222
[TBL] [Abstract][Full Text] [Related]
11. Binding, transcytosis and biodistribution of anti-PECAM-1 iron oxide nanoparticles for brain-targeted delivery.
Dan M; Cochran DB; Yokel RA; Dziubla TD
PLoS One; 2013; 8(11):e81051. PubMed ID: 24278373
[TBL] [Abstract][Full Text] [Related]
12. Fabrication of Curcumin Diethyl γ-Aminobutyrate-Loaded Chitosan-Coated Magnetic Nanocarriers for Improvement of Cytotoxicity against Breast Cancer Cells.
Hansapaiboon S; Bulatao BP; Sorasitthiyanukarn FN; Jantaratana P; Nalinratana N; Vajragupta O; Rojsitthisak P; Rojsitthisak P
Polymers (Basel); 2022 Dec; 14(24):. PubMed ID: 36559930
[TBL] [Abstract][Full Text] [Related]
13. Theranostic nanoparticles based on magnetic nanoparticles: design, preparation, characterization, and evaluation as novel anticancer drug carrier and MRI contrast agent.
Nosrati H; Salehiabar M; Kheiri Manjili H; Davaran S; Danafar H
Drug Dev Ind Pharm; 2018 Oct; 44(10):1668-1678. PubMed ID: 29848101
[TBL] [Abstract][Full Text] [Related]
14. Quantification and biodistribution of iron oxide nanoparticles in the primary clearance organs of mice using T
Zhang J; Ring HL; Hurley KR; Shao Q; Carlson CS; Idiyatullin D; Manuchehrabadi N; Hoopes PJ; Haynes CL; Bischof JC; Garwood M
Magn Reson Med; 2017 Aug; 78(2):702-712. PubMed ID: 27667655
[TBL] [Abstract][Full Text] [Related]
15. Bovine Serum Albumin (BSA) coated iron oxide magnetic nanoparticles as biocompatible carriers for curcumin-anticancer drug.
Nosrati H; Sefidi N; Sharafi A; Danafar H; Kheiri Manjili H
Bioorg Chem; 2018 Feb; 76():501-509. PubMed ID: 29310081
[TBL] [Abstract][Full Text] [Related]
16. Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings.
Feng Q; Liu Y; Huang J; Chen K; Huang J; Xiao K
Sci Rep; 2018 Feb; 8(1):2082. PubMed ID: 29391477
[TBL] [Abstract][Full Text] [Related]
17. Iron oxide nanoparticles for biomedical applications: an updated patent review (2015-2021).
Mao Z; Li X; Wang P; Yan H
Expert Opin Ther Pat; 2022 Sep; 32(9):939-952. PubMed ID: 35929879
[TBL] [Abstract][Full Text] [Related]
18. Biocompatible and fluorescent superparamagnetic iron oxide nanoparticles with superior magnetic properties coated with charged polysaccharide derivatives.
Lachowicz D; Szpak A; Malek-Zietek KE; Kepczynski M; Muller RN; Laurent S; Nowakowska M; Zapotoczny S
Colloids Surf B Biointerfaces; 2017 Feb; 150():402-407. PubMed ID: 27842931
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and Toxicity Assessment of Superparamagnetic Iron Oxide Nanoparticles In Vitro and In Vivo.
Yu Q; Xiong XQ; Zhao L; Xu TT; Bi H; Fu R; Wang QH
Curr Med Sci; 2018 Dec; 38(6):1096-1102. PubMed ID: 30536075
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution and targeting properties of iron oxide nanoparticles for treatments of cancer and iron anemia disease.
Alphandéry E
Nanotoxicology; 2019 Jun; 13(5):573-596. PubMed ID: 30938215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
